Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Muggia

Showing results (181-190 of 424) with videos related to

Pageof 43
Sort By:
Cancer Treatment Reports|August 1, 1978
Problems in the development of cytotoxic moieties linked to hormonesM E Lippman, J C Heuson, F M Muggia
Surgical Neurology|July 1, 1982
Acute appendicitis in children with a ventriculoperitoneal shuntM Hadani, G Findler, M Muggia-Sullam, et al.
Seminars in Oncology|December 1, 1981
The Cancer Therapy Evaluation Program of the National Cancer InstituteF M Muggia, S K Carter, J S Macdonald
Cancer Chemotherapy Reports|December 1, 1971
Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidine- -D-glucopyranoside) (NSC-122819)F M Muggia, O S Selawry, H H Hansen
Oncology (Williston Park, N.Y.)|April 5, 2011
Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when?Maria José Echarri Gonzalez, Robin Green, Franco M Muggia
Antibiotics and Chemotherapy|January 1, 1978
New anticancer drugsF M Muggia, V H Bono, V T DeVita
International Journal of Radiation Oncology, Biology, Physics|January 1, 1984
Role of chemotherapy in the treatment of lung cancer: evolving strategies for non-small cell histologiesF M Muggia, R H Blum, J D Foreman
Cancer Chemotherapy Reports|October 1, 1972
Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicityP J Creaven, L M Allen, F M Muggia
Cancer|June 1, 1973
Hypercalcemia in epidermoid tumors of the head and neck and esophagusR L Stephens, H H Hansen, F M Muggia
Biomedicine / [Publiee Pour L'A.A.I.C.I.G.]|December 1, 1977
Cytembena: an anticancer drug with an unique structureD D Von Hoff, M Rozencweig, F M Muggia
Pageof 43

Showing results (181-190 of 424) with videos related to

Sort By:
Pageof 43
Cancer Treatment Reports|August 1, 1978
Problems in the development of cytotoxic moieties linked to hormonesM E Lippman, J C Heuson, F M Muggia
Surgical Neurology|July 1, 1982
Acute appendicitis in children with a ventriculoperitoneal shuntM Hadani, G Findler, M Muggia-Sullam, et al.
Seminars in Oncology|December 1, 1981
The Cancer Therapy Evaluation Program of the National Cancer InstituteF M Muggia, S K Carter, J S Macdonald
Cancer Chemotherapy Reports|December 1, 1971
Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidine- -D-glucopyranoside) (NSC-122819)F M Muggia, O S Selawry, H H Hansen
Oncology (Williston Park, N.Y.)|April 5, 2011
Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when?Maria José Echarri Gonzalez, Robin Green, Franco M Muggia
Antibiotics and Chemotherapy|January 1, 1978
New anticancer drugsF M Muggia, V H Bono, V T DeVita
International Journal of Radiation Oncology, Biology, Physics|January 1, 1984
Role of chemotherapy in the treatment of lung cancer: evolving strategies for non-small cell histologiesF M Muggia, R H Blum, J D Foreman
Cancer Chemotherapy Reports|October 1, 1972
Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicityP J Creaven, L M Allen, F M Muggia
Cancer|June 1, 1973
Hypercalcemia in epidermoid tumors of the head and neck and esophagusR L Stephens, H H Hansen, F M Muggia
Biomedicine / [Publiee Pour L'A.A.I.C.I.G.]|December 1, 1977
Cytembena: an anticancer drug with an unique structureD D Von Hoff, M Rozencweig, F M Muggia
Pageof 43